ALK (G1202R)

ALK · Variant type: point · HGVS: p.G1202R

Drug response on this variant

#	Drug	Inhibition on variant	Residual	KISS
1	Lorlatinib	100.0%	0.0%	97.24
2	Brigatinib	97.5%	2.5%	82.96
3	Ceritinib	97.5%	2.5%	95.44
4	Crizotinib	95.8%	4.2%	91.39
5	Alectinib	95.4%	4.6%	95.49
6	Gilteritinib	86.7%	13.3%	88.97
7	Pralsetinib	85.9%	14.1%	93.43
8	Mobocertinib	83.3%	16.7%	97.22
9	Neratinib	82.1%	17.9%	93.18
10	Lazertinib	81.0%	19.0%	97.47
11	Pacritinib	81.0%	19.0%	88.64
12	Alpelisib	77.5%	22.5%	97.22
13	Canertinib	74.7%	25.4%	96.49
14	Vandetanib	73.4%	26.6%	95.74
15	Erlotinib	71.8%	28.2%	99.75
16	Ruxolitinib	70.3%	29.7%	98.25
17	Repotrectinib	65.8%	34.2%	84.21
18	Defactinib	62.4%	37.6%	92.68
19	Pemigatinib	57.0%	43.0%	98.23
20	Entrectinib	56.4%	43.6%	93.69
21	Baricitinib	52.0%	48.0%	97.99
22	Fedratinib	51.3%	48.7%	96.21
23	Bosutinib	48.1%	51.9%	87.22
24	Zanubrutinib	46.7%	53.3%	98.24
25	Fostamatinib	40.7%	59.3%	96.74

Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).

Drug	Variant inh	WT inh	Δ (variant − WT)
Lorlatinib	100.0%	97.2%	+2.8%
Brigatinib	97.5%	99.2%	-1.7%
Ceritinib	97.5%	98.3%	-0.8%
Crizotinib	95.8%	97.7%	-2.0%
Alectinib	95.4%	98.6%	-3.2%
Gilteritinib	86.7%	99.5%	-12.8%
Pralsetinib	85.9%	82.6%	+3.4%
Mobocertinib	83.3%	—	—
Neratinib	82.1%	—	—
Lazertinib	81.0%	46.3%	+34.7%
Pacritinib	81.0%	55.3%	+25.7%
Alpelisib	77.5%	80.7%	-3.2%
Canertinib	74.7%	—	—
Vandetanib	73.4%	—	—
Erlotinib	71.8%	—	—
Ruxolitinib	70.3%	52.1%	+18.2%
Repotrectinib	65.8%	99.4%	-33.6%
Defactinib	62.4%	—	—
Pemigatinib	57.0%	—	—
Entrectinib	56.4%	98.8%	-42.4%
Baricitinib	52.0%	46.4%	+5.7%
Fedratinib	51.3%	—	—
Bosutinib	48.1%	75.1%	-27.0%
Zanubrutinib	46.7%	—	—
Fostamatinib	40.7%	—	—

Cancer	Organ	Source
carcinoma_lung	Lung	ref
malignant_melanoma_skin	Skin	ref

Loading…

Served from saifudeen2026@1.0.0 · API 0.1.0 · 11.5ms